The NASH Roundtable has evolved into the Metabolic Continuum Roundtable™.
The NASH Roundtable has evolved into the Metabolic Continuum Roundtable™.
The NASH Roundtable was established in 2018 as a platform to stimulate collaboration and dialogue and to support the development of effective and safe treatments for steatotic liver disease. We are excited to announce a pivotal transformation in our organization’s identity and focus.
The NASH Roundtable has evolved into the Metabolic Continuum Roundtable, signifying our unwavering commitment to a holistic perspective on metabolic disorders. At the heart of this evolution lies the concept of the ‘continuum of metabolic diseases,’ where conditions like MASLD/MASH, obesity, diabetes, cardiovascular diseases, and chronic kidney disease are viewed as interconnected disorders sharing common risk factors and complex, bidirectional pathological processes, prompting us to explore new avenues for research, intervention, and collaboration.
The Metabolic Continuum Roundtable members represent cross-functional expertise in metabolic research, drug development, and patient care, and hail from prominent academic and medical centers in North America, Europe, and Asia. Brought together by their common commitment to steward advances in science, clinical research, and therapeutics, their collaborative efforts aim to improve patient outcomes and propel advancements in knowledge within the global scientific community.
View the Metabolic Continuum Roundtable: A Forum for Collaborative Science & Translational Clinical Research fact sheetKey Pillars of the Metabolic Continuum Roundtable Initiative
Comprised of leading scientific and clinical development experts in metabolic continuum diseases
Advancing science, methods, clinical planning, study design and protocol development for metabolic diseases
Accessible to biopharma to consult on metabolic disease development programs
